The machine-learning algorithm identified a compound that kills Acinetobacter baumannii, a bacterium that lurks in many hospital settings.
Using an artificial intelligence algorithm, researchers at MIT and McMaster University have identified a new antibiotic that can kill a type of bacteria that is responsible for many drug-resistant infections.
If developed for use in patients, the drug could help to combat Acinetobacter baumannii, a species of bacteria that is often found in hospitals and can lead to pneumonia, meningitis, and other serious infections. The microbe is also a leading cause of infections in wounded soldiers in Iraq and Afghanistan.
Acinetobacter baumannii is a species of bacteria commonly found in the environment, such as soil and water, but it can also inhabit human skin and healthcare environments. It’s known for its ability to survive on artificial surfaces for extended periods, making hospitals a common site for infection. It primarily affects people with compromised immune systems, causing a range of illnesses including pneumonia, blood infections, and meningitis. A. baumannii is particularly concerning because of its resistance to many antibiotics, leading to its classification as a “superbug.” As a result, infections can be challenging to treat, posing a significant threat to healthcare settings.
The researchers identified the new drug from a library of nearly 7,000 potential drug compounds using a machine-learning model that they trained to evaluate whether a chemical compound will inhibit the growth of A. baumannii.
“This finding further supports the premise that AI can significantly accelerate and expand our search for novel antibiotics,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering. “I’m excited that this work shows that we can use AI to help combat problematic pathogens such as A. baumannii.”
Collins and Stokes are the senior authors of the new study, which was published on May 25 in the journal Nature Chemical Biology. The paper’s lead authors are McMaster University graduate students Gary Liu and Denise Catacutan and recent McMaster graduate Khushi Rathod.
Drug discovery
Over the past several decades, many pathogenic bacteria have become increasingly resistant to existing antibiotics, while very few new antibiotics have been developed.
Several years ago, Collins, Stokes, and MIT Professor Regina Barzilay (who is also an author on the new study), set out to combat this growing problem by using machine learning, a type of artificial intelligence that can learn to recognize patterns in vast amounts of data. Collins and Barzilay, who co-direct MIT’s Abdul Latif Jameel Clinic for Machine Learning in Health, hoped this approach could be used to identify new antibiotics whose chemical structures are different from any existing drugs.
Using an artificial intelligence algorithm, researchers at MIT and McMaster University have identified a new antibiotic that can kill a type of bacteria (Acinetobacter baumannii, pink) that is responsible for many drug-resistant infections. Credit: Christine Daniloff/MIT; Acinetobacter baumannii image courtesy of CDC
In their initial demonstration, the researchers trained a machine-learning algorithm to identify chemical structures that could inhibit growth of E. coli. In a screen of more than 100 million compounds, that algorithm yielded a molecule that the researchers called halicin, after the fictional artificial intelligence system from “2001: A Space Odyssey.” This molecule, they showed, could kill not only E. coli but several other bacterial species that are resistant to treatment.
“After that paper, when we showed that these machine-learning approaches can work well for complex antibiotic discovery tasks, we turned our attention to what I perceive to be public enemy No. 1 for multidrug-resistant bacterial infections, which is Acinetobacter,” Stokes says.
To obtain training data for their computational model, the researchers first exposed A. baumannii grown in a lab dish to about 7,500 different chemical compounds to see which ones could inhibit growth of the microbe. Then they fed the structure of each molecule into the model. They also told the model whether each structure could inhibit bacterial growth or not. This allowed the algorithm to learn chemical features associated with growth inhibition.
Once the model was trained, the researchers used it to analyze a set of 6,680 compounds it had not seen before, which came from the Drug Repurposing Hub at the Broad Institute. This analysis, which took less than two hours, yielded a few hundred top hits. Of these, the researchers chose 240 to test experimentally in the lab, focusing on compounds with structures that were different from those of existing antibiotics or molecules from the training data.
Those tests yielded nine antibiotics, including one that was very potent. This compound, which was originally explored as a potential diabetes drug, turned out to be extremely effective at killing A. baumannii but had no effect on other species of bacteria including Pseudomonas aeruginosa, Staphylococcus aureus, and carbapenem-resistant Enterobacteriaceae.
This “narrow spectrum” killing ability is a desirable feature for antibiotics because it minimizes the risk of bacteria rapidly spreading resistance against the drug. Another advantage is that the drug would likely spare the beneficial bacteria that live in the human gut and help to suppress opportunistic infections such as Clostridium difficile.
“Antibiotics often have to be administered systemically, and the last thing you want to do is cause significant dysbiosis and open up these already sick patients to secondary infections,” Stokes says.
A novel mechanism
In studies in mice, the researchers showed that the drug, which they named abaucin, could treat wound infections caused by A. baumannii. They also showed, in lab tests, that it works against a variety of drug-resistant A. baumannii strains isolated from human patients.
Further experiments revealed that the drug kills cells by interfering with a process known as lipoprotein trafficking, which cells use to transport proteins from the interior of the cell to the cell envelope. Specifically, the drug appears to inhibit LolE, a protein involved in this process.
All Gram-negative bacteria express this enzyme, so the researchers were surprised to find that abaucin is so selective in targeting A. baumannii. They hypothesize that slight differences in how A. baumannii performs this task might account for the drug’s selectivity.
“We haven’t finalized the experimental data acquisition yet, but we think it’s because A. baumannii does lipoprotein trafficking a little bit differently than other Gram-negative species. We believe that’s why we’re getting this narrow spectrum activity,” Stokes says.
Stokes’ lab is now working with other researchers at McMaster to optimize the medicinal properties of the compound, in hopes of developing it for eventual use in patients.
The researchers also plan to use their modeling approach to identify potential antibiotics for other types of drug-resistant infections, including those caused by Staphylococcus aureus and Pseudomonas aeruginosa.

News
The Surprising Origin of a Deadly Hospital Infection
C. diff might not originate from external transmission but rather from within the infected patient themselves. Hospital staff dedicate significant effort to safeguard patients from infections during their hospital stay. Through practices ranging from [...]
Google AI breakthrough – huge step in finding genes that cause diseases
Google says it has made a significant step in identifying disease-causing genes, which could help spot rare genetic disorders. A new model named AlphaMissense is able to confidently classify 89 per cent of all [...]
New Study: Everyday Pleasures Can Boost Cognitive Performance
MINDWATCH study reveals cognitive peaks with everyday pleasures. Listening to music and drinking coffee are the sorts of everyday pleasures that can impact a person’s brain activity in ways that improve cognitive performance, including [...]
Moderna reveals new highly targeted COVID-19 vaccine mRNA-1283
Moderna has developed a new and improved version of its COVID-19 vaccine. The unique formulation (mRNA-1283) reduces the vaccine's content from the full-length SARS-CoV-2 spike protein to a narrowly focused encoding of just two [...]
New nanotech weapon takes aim at hard-to-treat breast cancer
Breast cancer in its various forms affects more than 250,000 Americans a year. One particularly aggressive and hard-to-treat type is triple-negative breast cancer (TNBC), which lacks specific receptors targeted by existing treatments. The rapid [...]
Scientists upcycle plastics into liquids that can store hydrogen energy
Scientists from Nanyang Technological University, Singapore (NTU Singapore) have created a process that can upcycle most plastics into chemical ingredients useful for energy storage, using light-emitting diodes (LEDs) and a commercially available catalyst, all [...]
Yale Scientists Uncover How the Immune System Can Alter Our Behavior
The mere scent of seafood can severely sicken those allergic to it — and therefore they are more likely to avoid it. Similarly, individuals who experience food poisoning from a specific dish tend to [...]
Whirlwind Tech – The Future of Energy-Efficient Spintronics Computing
Researchers in Germany and Japan have been able to increase the diffusion of magnetic whirls, so-called skyrmions, by a factor of ten. In today’s world, our lives are unimaginable without computers. Up until now, [...]
Omicron’s Silver Lining: Significantly Lower Risk of Long COVID
Omicron infections have a lower risk of long COVID than earlier variants, according to a study analyzing data from 11,000 participants. The risk of developing long COVID is significantly lower following an infection with [...]
The Hidden Mechanism Connecting Diabetes and Cancer
Researchers have discovered that insulin resistance, typically linked with type 2 diabetes, is also present in cancer patients and can accelerate the spread of the disease. In the 1920s, scientists found that the urine [...]
Scientists Unveil Urea’s Secret Role in the Origin of Life
Scientists from ETH Zurich and the University of Geneva have developed a new technique that allows them to observe chemical reactions taking place in liquids at extremely high temporal resolution. This innovation enables them to track how molecules [...]
Viagra Lowers Alzheimer’s Risk by Almost 70%, Early Study Finds
Research published recently suggests that Pfizer’s erectile dysfunction drug Viagra can decrease the risk of developing Alzheimer’s disease by up to 69 percent. The research, which was published in Nature, found that the medication has [...]
Future of Medical Imaging: Advanced AI Can Tell Your True Age by Looking at Your Chest
An AI-powered model utilizes chest X-rays to help develop biomarkers for aging. What if determining “your age” was based on your chest rather than your face? Scientists from Osaka Metropolitan University have crafted an [...]
Ultra-sensitive biosensors detect cancer in a blood test
Cancer biomarkers circulating in body fluids can be used for diagnosis and treatment monitoring. However, current detection technology lacks the required sensitivity, limiting biomarker use in clinical applications. Colorectal cancer is the second most [...]
Viruses cause 200+ diseases. This one drug may be able to treat them all.
By taking aim at a process common across many viruses, the drug could one day stop any number of known viruses — and new ones. t’s about as audacious an idea as you can [...]
Scientists Identify Potential Treatment for Rare and Devastating Lung Disease
The findings could lead to a cure for LAM. Researchers from the University of Cincinnati may have identified a potential treatment for lymphangioleiomyomatosis (LAM), a rare lung condition resembling cancer found predominantly in women of reproductive [...]